Cohance Lifesciences Limited
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Operating margin of 38.6% exceeds Healthcare median (24.8%)
Concerns1
- Operating margin declining for 3 consecutive years (44.0% β 39.0% β 33.0%)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 7 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.09 K Cr | β | βΉ272.00 Cr | β | β | 11.7% | 4.1% | -8.1% |
| Mar 2024 | βΉ1.05 K Cr | β | βΉ296.00 Cr | β | β | 14.6% | -21.0% | -31.6% |
| Mar 2023 | βΉ1.33 K Cr | β | βΉ433.00 Cr | β | β | 24.8% | 0.8% | -22.4% |
| Mar 2022 | βΉ1.32 K Cr | β | βΉ558.00 Cr | β | β | 36.7% | 30.7% | 80.6% |
| Mar 2021 | βΉ1.01 K Cr | β | βΉ309.00 Cr | β | β | 29.0% | 21.1% | 14.4% |
| Mar 2020 | βΉ834.00 Cr | β | βΉ270.00 Cr | β | β | 34.5% | 120.6% | 147.7% |
| Mar 2019 | βΉ378.00 Cr | β | βΉ109.00 Cr | β | β | β | -65.4% | -59.9% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,034 |
| Total Expenses | 1,463 |
| EBIT / Operating Profit | 571 |
| OPM % | 28% |
| Other Income | 39 |
| Finance Costs | 22 |
| Depreciation & Amortisation | 120 |
| Profit Before Tax | 469 |
| Tax % | - |
| Net Profit / PAT | 353 |
| EPS (βΉ) | 11.94 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Cohance Lifesciences Limitedthis co. | βΉ17.16 K Cr | βΉ1.09 K Cr | 46.30 | 3.90 | 37.00 | 4.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |